Abstract
Obstructive sleep apnoea is a common, multifactorial condition with obesity as its most important modifiable driver. Weight loss can markedly reduce disease severity, and the recent TGA approval of tirzepatide for obstructive sleep apnoea in adults with obesity offers a novel adjunct to continuous positive airway pressure, broadening treatment strategies and improving long-term health outcomes.
| Original language | English |
|---|---|
| Pages (from-to) | 41-45 |
| Number of pages | 5 |
| Journal | Medicine Today |
| Volume | 26 |
| Issue number | 9 |
| Publication status | Published - Sept 2025 |
Fingerprint
Dive into the research topics of 'Obesity and obstructive sleep apnoea: exploring the role of tirzepatide'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver